… application of monoclonal antibodies (mAbs) to oncology have been the introduction and
approval of bevacizumab (Avastin), an anti–vascular endothelial growth factor antibody, and of …

… therapy using unmodified monoclonal antibodies has, however, been elusive. Recently,
monoclonal antibodymediated therapy … targets for effective monoclonal antibody action, genetic …

… for the production of monoclonal antibodies(MAb) by Kohler & Milstein 25 years ago led to
the development of multiplereagents employing these structures. Antibodies, which initially …

The therapeutic potential of monoclonal antibodies (mAb) was quickly realised after the
hybridoma technique allowed their development in the mid 1970s. Chimeric humanised and fully …

… mAb therapy from treatments such as chemotherapy and underlies the capability of antibodies
… To better understand how monoclonal antibodies function as a cancer therapy, we review …

… However, these two processes alone do not explain the therapeutic efficacy of antibody
therapy; they also act by apoptotic signaling and growth inhibitory pathways. Conjugation of …

… Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis …
insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, …

Monoclonal antibodies (MoAbs) are increasingly used in the treatment of patients with
hematological malignancies and autoimmune diseases. The most commonly employed …

… The therapeutic potential of monoclonal antibodies has been … the potential monoclonal
antibody based therapeutic … knowledge on the neutralizing monoclonal antibodies against similar …

… Monoclonal antibody-based treatment of cancer has been established as one of the most
successful therapeutic strategies for both hematologic malignancies and solid tumors in the …